HealthPartners is an integrated, nonprofit health care provider and health insurance company located in Bloomington, Minnesota offering care, coverage, research and education to its members, patients and the community.
BackgroundRepurposing therapeutic treatments for diabetes may be a promising strategy for the treatment of neurodegenerative disorders. Intranasal insulin (INI) is shown to improve memory, attention, and cognition in Alzheimer’s dementia. Associations between the etiology of Parkinson’s Disease (PD), brain glucose hypometabolism, and central insulin resistance suggest INI as a promising treatment for PD.MethodsA phase II single center, randomized, double-blind clinical trial was conducted in 30 participants with PD, aged 41–89, MoCA ≥ 16, on a stable dose of anti-PD medications. Participants were randomized to receive intranasal treatment for 21 days with either placebo, or 20, 40, or 80 IU of regular insulin (INI) using SipNose intranasal device. Primary outcomes of safety and tolerability were assessed in 30 participants by monitoring hypoglycemia, weight, and adverse events. Cognitive, mood, and motor measures were collected pre- and post-treatment for secondary outcome analysis and assessed in 28 participants.ResultsNo significant changes in weight or serum insulin were observed during the study. No hypoglycemic values (<70 mg/dL) were recorded 15 or 30 min post-IN dose. Nasal irritation and nosebleeds were the most common adverse events, with most categorized as “mild.” Several secondary outcomes (e.g., verbal fluency and recall) improved from baseline in the 40 IU/INI arm only, though not significantly more than in the placebo arm. No other outcomes assessed (mood, apathy, motor) improved under INI treatment.ConclusionINI exhibits an acceptable safety profile in patients with PD. Further studies to investigate if INI has a positive impact on cognitive and motor symptoms in PD are warranted.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT04251585 Identifier, NCT04251585.
OBJECTIVES:To evaluate the use of standardized protocols for reflexing to broad, multigene panels in non-small cell lung cancer (NSCLC) and identify barriers that limit timely pathologist‑ordered biomarker reflex testing. METHODS:A cross-sectional survey was administered to a national sample of health care professionals involved in NSCLC biomarker testing. RESULTS:Of 111 respondents in the dataset, 77.5% reported using an institutional standardized protocol for comprehensive biomarker testing (CBT), and 88.4% of these protocols included reflexing to a multigene panel. Most respondents with reflex protocols indicated that 80% or more of newly diagnosed patients with NSCLC received CBT; however, fewer respondents reported that results were available before the oncology visit to select first‑line treatment. Pathologists were the primary ordering providers in institutions with standardized protocols. Respondents agreed that pathologist‑ordered reflex biomarker testing improves cancer care and supported Centers for Medicare & Medicaid Services (CMS) recognition of pathologists as ordering physicians for broad biomarker panels. Despite protocol adoption, respondents cited persistent barriers-including reimbursement, insurance authorization delays, and the Medicare 14-day rule. CONCLUSIONS:Locally standardized protocols incorporating reflex multigene panel testing have been reported and are associated with high rates of CBT. Institutional and operational barriers delay the availability of results and limit the impact of these protocols on first‑line treatment decisions. Clarifying CMS guidance on pathologists as valid ordering physicians for broad biomarker panels, strengthening coordination with multidisciplinary teams, addressing workflow constraints, and educating the laboratories and payers on pathologists having ordering authority may enhance the effectiveness and adoption of reflex biomarker testing models.
Obesity is the most prevalent chronic condition, although it was not officially recognized as a disease until 2013. Obesity is complex and directly contributes to many other chronic conditions. Recently, new medications have become available, which are valuable tools for the treatment of obesity. With or without medication, lifestyle interventions remain fundamental in the treatment of obesity. As demonstrated by the case presented, even patients with severe obesity (BMI 45.8) can achieve remarkable improvement (BMI 31.7) through intensive lifestyle interventions without medication. Achieving weight loss significantly improves clinical outcomes and helps curb the rise of obesity and its complications. Providers are well positioned to provide intensive lifestyle therapeutic interventions for patients with obesity.
Abstract Background: STK-012 is a first-in-class α/β-IL-2R biased partial agonist that drives antitumor activity by selectively stimulating CD25+ antigen-activated T-cells and avoids hallmark IL-2 toxicities by sparing pleiotropic activation of lymphocytes including NK cells. In this phase 1a/b study, STK-012 is combined with standard of care pembrolizumab + chemotherapy (PCT) in 1L PD-L1 negative NSQ NSCLC where PCT alone has poor outcomes (ORR 32% and median PFS 6.2 months). Methods: 1L NSQ NSCLC subjects received STK-012 SC Q3W + PCT. Serial blood samples were analyzed for changes in cytokines in chemoluminescence assays, T cell proliferation and activation markers were analyzed in spectral flow cytometry, and T cell clonality was analyzed by TCR sequencing. Data are shown for a cohort of 22 efficacy-evaluable 1L NSCLC subjects (N=18 PD-L1<1%, N=4 PD-L1=1%) which was enriched for loss-of-function tumor suppressor gene (LoF TSG) mutations (n=11; STK11, KEAP1, SMARCA4) or mucinous histology (n=5) associated with a “cold” TME and primary immune resistance. Results: STK-012 + PCT demonstrated an ORR of 55% in all efficacy evaluable patients; 50% in patients with PD-L1<1% tumors; 55% in LoF TSG mutations; and 80% in mucinous histology. STK-012 + PCT induced sustained proliferation of CD8+ and CD4+ T cells (13X and 5x increase from baseline, respectively), proliferation of antigen activated T cells including PD-1+ CD8+ (14X) and 4-1BB+ CD8+ (14X) and re-invigoration and proliferation of previously exhausted CD39+ (11x) and TIM3+ (18x) CD8+ T cells. After the first cycle, 3.35% of the total T cell repertoire were T cell clones which were newly detected or expanded >10x (n=12). STK-012 + PCT induced key cytokines IFNγ and IL-18 characterizing an activated CD8+ T cell response and increased IP-10 which is associated with enhanced T cell trafficking into tumor tissues (13x,14x and 23x mean increase from baseline, respectively). Sustained elevation of cytokines across treatment cycles (IFNγ median peak of 71, 95, 96 pg/mL in C1, C2 and C6) was observed, supportive of the emerging durability of the combination. Induction of cytokines TNFα and IL-6 was limited (median peak 4, 6 pg/mL), consistent with limited activation of naïve T cells and NK cells and the lack of capillary leak syndrome with STK-012. Conclusions: STK-012 + PCT led to robust cytokine induction, proliferation and expansion of antigen activated T cells, proliferation of previously exhausted T cells, and remodeling of the T cell repertoire. The addition of STK-012 to PCT has the potential to overcome resistance in immune excluded populations including PD-L1<1% tumors, LoF TSG mutations and mucinous histology. A global, randomized Phase 2 study, SYNERGY-101, of STK-012 + PCT vs. PCT in 1L PD-L1<1% NSQ NSCLC is ongoing (NCT05098132). Citation Format: Salman Punekar, Adam Jacob Schoenfeld, Edward B. Garon, So Yeon Kim, Kai He, Jennifer Marks, Brian S. Henick, Stephen V. Liu, Nagashree Seetharamu, Alexander Spira, Justin Gainor, Tim Larson, Ticiana A. Leal, Cameron Oswalt, Benjamin Izar, Alize Marangoz-Stager, Vic Danh, Grace Lunardi, Krystle Bach, Naiyer A. Rizvi, Alex Azrilevich, Anita Mehta-Damani, Martin Oft. Selective immune activation of antigen activated T cells with STK-012, an a/b IL-2 receptor biased partial agonist, with pembrolizumab and chemotherapy in 1L PD-L1 negative non-squamous NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6740.
Background: Automated insulin delivery (AID) systems are recommended for individuals with diabetes requiring insulin. Real-world effectiveness may differ from outcomes reported in prospective clinical trials. The twiist (TM) AID system recently received regulatory clearance, and real-world glycemic outcomes have not been previously described. Methods: This was an ongoing retrospective, observational real-world study with cross-sectional analyses of participant-level summary data. The analysis included individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) who initiated use of the twiist AID system and consented to data sharing. Deidentified continuous glucose monitoring (CGM) and insulin delivery data were analyzed. Inclusion in the analysis required >= 14 days of device use. Glycemic outcomes were assessed using standard CGM metrics, including percent time in range (%TIR; 70-180 mg/dL), time in tight range (%TITR; 70-140 mg/dL), time below range (%TBR; 54 to <70 and <54 mg/dL), and time above range (%TAR; >180-250 and >250 mg/dL). Subgroup analyses evaluated associations with baseline glycated hemoglobin (HbA1c), age, and bolus frequency. Results: Data from 4000 individuals were included. The duration of device use ranged from a minimum of 14 days to a maximum of 365 days. Mean overall %TIR was 73.5 +/- 14.5%, with overnight %TIR of 77.9 +/- 16.5%. Hypoglycemia exposure was low, with mean overall %TBR of 54 to <70 mg/dL of 1.9 +/- 2.0% and <54 mg/dL of 0.2 +/- 0.4%. Glycemic outcomes were generally within recommended targets across age categories except for %TIR among those <18 years of age. Among those with baseline HbA1c values and TIR values (n = 1131), %TIR was 81.5 +/- 10.2% and 71.1 +/- 11.4%, and 61.7 +/- 16.3% for those HbA1c <7%, 7%-8%, and >8%, respectively. More frequent boluses were associated with improved glycemic outcomes. Conclusions: In this large real-world cohort, use of the twiist AID system was associated with effective overall and overnight glycemic management and minimal hypoglycemia.